Olaf Hardt

1.3k total citations
33 papers, 616 citations indexed

About

Olaf Hardt is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Olaf Hardt has authored 33 papers receiving a total of 616 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 11 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Olaf Hardt's work include Cancer Cells and Metastasis (12 papers), CAR-T cell therapy research (10 papers) and Cancer Research and Treatments (5 papers). Olaf Hardt is often cited by papers focused on Cancer Cells and Metastasis (12 papers), CAR-T cell therapy research (10 papers) and Cancer Research and Treatments (5 papers). Olaf Hardt collaborates with scholars based in Germany, France and United States. Olaf Hardt's co-authors include Andreas Bosio, Harold Cremer, Wa’el Al Rawashdeh, Ralph Seidenfaden, Sandra Goebbels, Antoine de Chevigny, Camille Boutin, Nathalie Coré, Stefan Müller and Thomas Langer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and PLoS ONE.

In The Last Decade

Olaf Hardt

29 papers receiving 605 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olaf Hardt Germany 12 319 250 98 81 80 33 616
Parvez Vora Canada 12 259 0.8× 124 0.5× 69 0.7× 74 0.9× 53 0.7× 25 550
David Cory Adamson United States 15 481 1.5× 162 0.6× 111 1.1× 76 0.9× 22 0.3× 31 992
Montserrat Lara‐Velazquez United States 14 253 0.8× 88 0.4× 134 1.4× 70 0.9× 37 0.5× 28 657
Aishwarya Nene United States 7 532 1.7× 215 0.9× 128 1.3× 93 1.1× 134 1.7× 9 840
Edward Visse Sweden 16 242 0.8× 247 1.0× 51 0.5× 305 3.8× 69 0.9× 38 756
Bong Gu Kang South Korea 13 564 1.8× 364 1.5× 60 0.6× 63 0.8× 97 1.2× 22 1.1k
Andrew J. Storaska United States 8 483 1.5× 199 0.8× 142 1.4× 49 0.6× 51 0.6× 9 724
Lisa Mohamet United Kingdom 14 385 1.2× 103 0.4× 125 1.3× 133 1.6× 63 0.8× 19 715
Jérôme Kroonen Belgium 13 371 1.2× 131 0.5× 40 0.4× 120 1.5× 80 1.0× 18 758
Angeliki Mela United States 14 528 1.7× 65 0.3× 82 0.8× 70 0.9× 68 0.8× 22 825

Countries citing papers authored by Olaf Hardt

Since Specialization
Citations

This map shows the geographic impact of Olaf Hardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf Hardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf Hardt more than expected).

Fields of papers citing papers by Olaf Hardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olaf Hardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf Hardt. The network helps show where Olaf Hardt may publish in the future.

Co-authorship network of co-authors of Olaf Hardt

This figure shows the co-authorship network connecting the top 25 collaborators of Olaf Hardt. A scholar is included among the top collaborators of Olaf Hardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olaf Hardt. Olaf Hardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hardt, Olaf, et al.. (2025). Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects. International Journal of Molecular Sciences. 26(19). 9714–9714.
2.
Wittwer, Arthur J., Benjamin Theek, Olaf Hardt, et al.. (2025). Precision-cut tumor tissue slices, a novel tool to study the tumor microenvironment interactions with chimeric antigen receptor (CAR) T cells. PLoS ONE. 20(8). e0327322–e0327322.
3.
Bartkowiak, Kai, Stefan Werner, Antje Andreas, et al.. (2025). Discovery of a sushi domain-containing protein 2-positive phenotype in circulating tumor cells of metastatic breast cancer patients. Scientific Reports. 15(1). 3913–3913. 2 indexed citations
4.
Bosio, Andreas, et al.. (2024). Colorectal cancer-associated fibroblasts inhibit effector T cells via NECTIN2 signaling. Cancer Letters. 595. 216985–216985. 16 indexed citations
5.
Femel, Julia, et al.. (2024). Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer. International Journal of Molecular Sciences. 25(1). 615–615. 4 indexed citations
6.
Rawashdeh, Wa’el Al, Dominik Lock, Christoph Herbel, et al.. (2023). Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice. International Journal of Molecular Sciences. 24(11). 9184–9184. 7 indexed citations
7.
Hardt, Olaf, et al.. (2023). Basal‐like mammary carcinomas stimulate cancer stem cell properties through AXL‐signaling to induce chemotherapy resistance. International Journal of Cancer. 152(9). 1916–1932. 4 indexed citations
8.
Seitz, Alexander, Julia Franzen, Carlos A. García‐Prieto, et al.. (2023). Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome. Leukemia. 37(9). 1868–1878. 18 indexed citations
9.
Hardt, Olaf, Elke Roeb, Sarah K. Schröder, et al.. (2022). Isolation of Hepatocytes from Liver Tissue by a Novel, Semi-Automated Perfusion Technology. Biomedicines. 10(9). 2198–2198. 1 indexed citations
10.
Kinkhabwala, Ali, Felix Gremse, Melanie Jungblut, et al.. (2022). A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level. Theranostics. 12(11). 4834–4850. 11 indexed citations
11.
12.
Herbel, Christoph, Daniel Schaefer, Jutta Kollet, et al.. (2019). Abstract 4694: Evaluation of tumor-associated antigen expression with the MACSimaTMhigh-content imaging platform. Tumor Biology. 4694–4694. 1 indexed citations
13.
Domingues, Patrícia H., Lalitha S.Y. Nanduri, Cristina Viganó, et al.. (2017). Cellular Prion Protein PrPC and Ecto-5′-Nucleotidase Are Markers of the Cellular Stress Response to Aneuploidy. Cancer Research. 77(11). 2914–2926. 8 indexed citations
14.
Lock, Dominik, Nadine Mockel-Tenbrinck, Daniela Mauer, et al.. (2017). Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. Human Gene Therapy. 28(10). 914–925. 85 indexed citations
15.
Tomiuk, Stefan, Stefan M. Wild, Silvia Rüberg, et al.. (2016). Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells. Journal of Visualized Experiments.
16.
Tomiuk, Stefan, Stefan Wild, Silvia Rüberg, et al.. (2016). Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells. Journal of Visualized Experiments. 7 indexed citations
17.
Bayindir‐Buchhalter, Irem, Silvia Kocanova, Isabel Sousa, et al.. (2015). Transcriptional Pathways in cPGI2-Induced Adipocyte Progenitor Activation for Browning. Frontiers in Endocrinology. 6. 129–129. 27 indexed citations
18.
Boutin, Camille, Olaf Hardt, Antoine de Chevigny, et al.. (2009). NeuroD1 induces terminal neuronal differentiation in olfactory neurogenesis. Proceedings of the National Academy of Sciences. 107(3). 1201–1206. 122 indexed citations
19.
Hardt, Olaf, Corinna Scholz, Yuchio Yanagawa, et al.. (2008). Gene expression analysis defines differences between region-specific GABAergic neurons. Molecular and Cellular Neuroscience. 39(3). 418–428. 10 indexed citations
20.
Augustin, Steffen, et al.. (2004). Characterization of Peptides Released from Mitochondria. Journal of Biological Chemistry. 280(4). 2691–2699. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Parvez Vora Breakdown of academic impact, for papers by David Cory Adamson Breakdown of academic impact, for papers by Montserrat Lara‐Velazquez Breakdown of academic impact, for papers by Aishwarya Nene Breakdown of academic impact, for papers by Edward Visse Breakdown of academic impact, for papers by Bong Gu Kang Breakdown of academic impact, for papers by Andrew J. Storaska Breakdown of academic impact, for papers by Lisa Mohamet Breakdown of academic impact, for papers by Jérôme Kroonen Breakdown of academic impact, for papers by Angeliki Mela
Rankless by CCL
2026